Canntab Therapeutics (CSE: PILL.CN) (OTCQX: CTABF) (FRA: TBF1.F), a Canadian firm specializing in cannabinoid and terpene blends in hard pill form for therapeutic application, has received an initial assessment from the Geneva-based International Preliminary Report on Patentability (IPRP) for its Immediate Release Cannabidiol Formulation.
The IPRP has indicated a positive finding of patentability, meaning that Canntab’s formulation is patentable and novel. The Ontario-based company has already completed national filings in the U.S. and internationally as well as completed the international application process in Canada and Australia.
“This is a first and an important indication that our Immediate Release Cannabidiol Formulation is unique and patentable. It is our intention to build on this success as we continue to seek additional patents in Canada, United States and internationally. Our extensive portfolio of proprietary hard tablets is our core value proposition and we believe that we are well-positioned to be the dominant player in hard tablet cannabinoid formulations world-wide,” stated Jeff Renwick, co-founder and CEO of Canntab.
Canntab is a drug pharmaceutical company that has created a line of patent-pending precision oral delivery hard tablets. The company’s technology enables it to convert THC and CBD oil into a nano-emulsified granulation, and ultimately into a hard pill format.
Canntab has filed 13 patents in Canada and U.S. that cover a range of processes and formulations it needs to create its precision oral delivery hard tablets, the future of medical cannabis. These patents include Canntab’s nano-emulsification technology, granulation process, methods of manufacturing, and covers it’s full line of precision oral delivery hard tablets.
